Lung Cancer

A recently discovered enzyme could lead to the development of a treatment where cancer cells are starved of ‘food’ provided by this protein… UT Southwestern researchers have found that an enzyme on the surface of some lung cancer cells helps feed the cancer, making it a tempting treatment target. The enzyme, transmembrane serine protease 11B (TMPRSS11B) is described in a recent study. In addition to being found in squamous cell lung cancer and prostate cancer, the enzyme also has been identified in squamous cell head, neck, and cervical cancers, said Dr Kathryn O’Donnell , Assistant Professor of Molecular Biology. Her team identified TMPRSS11B while searching for genes that can convert precancerous lung cells into malignant cells that can form tumors. “In this study, we found that the enzyme strongly promoted the growth of certain types of lung cancer cells. We uncovered a new mechanism that expands our understanding of how cancer cells reprogram their metabolism to provide ener

Lung cancer symptoms don’t tend to be obvious until the cancer has progressed. They can also be mistaken for less serious health conditions. Any symptoms associated with the disease should be taken seriously, as lung cancer is one of the most common and serious types of cancer. As you would assume, lung cancer can affect a person’s chest. But what excatly does it feel like in a person's chest? Many people with lung cancer cite they feel “lung pain” before they are diagnosed with lung cancer. They also describe the pain as worse with deep breathing, coughing or laughing. Because lung cancer can cause shortness of breath, a person may also feel tightness in their chest. One of the most notable symptoms of lung cancer, the cough, may also cause pain and throbbing. A lung cancer cough can be confused for asthma - a less serious health condition. But how can you tell if your cough is linked to lung cancer? There are three signs to look out for, according to Cancer Research UK

A recently discovered enzyme could lead to the development of a treatment where cancer cells are starved of ‘food’ provided by this protein… UT Southwestern researchers have found that an enzyme on the surface of some lung cancer cells helps feed the cancer, making it a tempting treatment target. The enzyme, transmembrane serine protease 11B (TMPRSS11B) is described in a recent study. In addition to being found in squamous cell lung cancer and prostate cancer, the enzyme also has been identified in squamous cell head, neck, and cervical cancers, said Dr Kathryn O’Donnell , Assistant Professor of Molecular Biology. Her team identified TMPRSS11B while searching for genes that can convert precancerous lung cells into malignant cells that can form tumors. “In this study, we found that the enzyme strongly promoted the growth of certain types of lung cancer cells. We uncovered a new mechanism that expands our understanding of how cancer cells reprogram their metabolism to provide ener

November is Lung Cancer Awareness Month, and our Lung Cancer Special Issue is offering new insights into the treatment of the disease. BY Brielle Benyon and Katie Kosko PUBLISHED November 28, 2018 [embedded content] November is Lung Cancer Awareness Month, and our Lung Cancer Special Issue is offering new insights into the treatment of the disease. Read about how researchers are " Targeting Innovation " for small cell lung cancer, and how new treatment methods are offering " A Breath of Fresh Air " for advanced non-small cell lung cancer. You'll also hear from survivors who are " Alive & Kicking " and won't let treatment side effects slow them down. The issue also addresses the unsung heroes of cancer, the caregivers, in our "Caregivers' Corner." To read these stories and more, visit https://www.curetoday.com/publications/cure/2018/lung-2-2018 https://ift.tt/2r8my5w

Lynn Sherwood-Humphries knows better than anyone that lung cancer doesn’t change just the lives of smokers. The disease also stalks people like her daughter Lauren Sherwood-Sutherland, an otherwise healthy nonsmoker. Her 25-year-old daughter died May 21 after battling the disease . Traditional lung cancer prevention strategies wouldn’t have saved her. “Lung cancer isn’t what you think it is,” Lynn Sherwood-Humphries said. “If you have lungs you can get lung cancer.” During lung cancer awareness month, which is November, and all the months to come, Sherwood-Humphries said she’s an unstoppable “mom on a mission” trying to raise awareness for the disease and how imperative it is to find it early. “If there’s something to be learned from this, why not start the conversation,” she said. “It’s not a sexy conversation. It’s a hard conversation to have, but let’s have it.” At the time of her diagnosis last December, Sherwood-Sutherland had been married for two years and

Deepa S. Subramaniam, MBBS, MSc Next-generation sequencing (NGS) should be used for all patients with newly diagnosed lung cancer to identify the most personalized treatment approaches, some of which are becoming available for patients with ROS1 -positive disease, said Deepa S. Subramaniam, MBBS, MSc. In ROS1 -positive non–small cell lung cancer (NSCLC), crizotinib (Xalkori) is the only FDA-approved drug; however, others have shown promise in recent clinical trials. For example, in the ongoing, phase I/II TRIDENT-1 study, repotrectinib (TPX-0005) demonstrated a clinically meaningful and durable benefit across multiple doses in patients with ROS1 -positive NSCLC. Overall response rates (ORRs) were 80% (95% CI, 44%-97%) for TKI-naïve patients and 18% (95% CI, 4%-44%) for TKI-refractory patients, including 33% for those who received a dose of 160 mg once daily. A range of solid tumors were treated, with the most common being NSCLC (83%). In an interview with OncLive ® at the 2018 S

[unable to retrieve full-text content] Screenings available for lung cancer - The Tidewater News    Tidewater News Lung cancer is the leading cancer killer of men and women in the United States. Other cancers may get more attention and more funding, but lung cancer ... https://ift.tt/2zG8FAz

DE SOTO, Kan.--( BUSINESS WIRE )-- Oncimmune  Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialization of personalized immunodiagnostics for the screening, detection and care of cancer, today announced that it has entered into an agreement with MultiPlan to expand access to Oncimmune’s Early CDT—Lung test. Early CDT—Lung is a simple, affordable, and extensively studied blood test that helps clinicians to optimize risk assessment of malignancy in indeterminate pulmonary nodules (IPNs). MultiPlan, Inc. is one of the most comprehensive providers of healthcare cost management solutions that includes primary, complementary and out-of-network strategies for managing the financial risks associated with healthcare claims. The company contracts with 900,000 healthcare providers across the U.S. and has an estimated 57 million consumers accessing MultiPlan network products. “We are successfully establishing agreements with regional and national commercial heal

You could lower your risk of early death by eating a healthy, balanced diet, including at least five portions of fruit and vegetables a day, said the NHS . Regular exercise is also crucial for  boosting your lifespan . Everyone should aim for at least 150 minutes of moderate-intensity activity every week. Making some small dietary changes could also help to  increase your life expectancy . You could lower your chances of developing lung cancer by eating more avocado, it’s been claimed. Lung cancer is one of the most common cancers to be diagnosed in the UK, with around 45,000 new cases every year. Avocado, which is rich in vitamin E, could help to slash your risk of the disease, according to dietitian Juliette Kellow and nutritionist Dr Sarah Brewer. The vitamin helps to keep the lungs healthy, and avocado is one of the best sources of the nutrient, they said. “The lungs and respiratory tract respond well to support from nutrition,” they said in their book, ‘Eat Better Live

SCRANTON, LACKAWANNA COUNTY (WBRE/WYOU) - Breast cancer, colon cancer and pancreatic cancer are all among the deadliest forms of cancer. But each of those trails the number one cancer killer in the world: lung cancer.        The National Cancer Institute reports more than 150,000 Americans die annually of lung cancer. 3 million are currently under treatment for it. But as Eyewitness News Healthbeat Reporter Mark Hiller explains, how you're treated depends on how far along the cancer has progressed. "About three-quarters of people who are diagnosed with lung cancer come with a late stage lung cancer," said Geisinger Cardiothoracic Surgeon James Klena. So why do most lung cancer patients go without diagnosis until stage 3 or 4? Dr. Klena says it's because most are smokers who, because of their habit, already experience symptoms otherwise linked to lung cancer. "That is a cough, shortness of breath, frequent pneumonias." Unlike patients with stage 1 or 2 lu

Bristol-Myers Squibb ( BMY ) on Tuesday dipped to its lowest point this month after its immunotherapy regimen failed as a small cell lung cancer treatment. X On the stock market today , Bristol stock slipped 3% to 51.15. Bristol stock, however, remained within the bounds of a consolidation period and a buy point at 63.79. At the same time, shares of its closest rival, Merck ( MRK ), lifted 1.2% to 76.34. The pharmaceutical giant tested immunotherapy drugs Opdivo and Yervoy as a maintenance treatment for patients with small cell lung cancer. Patients had already completed a round of chemotherapy and their cancer hadn't worsened. But the immunotherapy regimen failed to improve overall survival in lung cancer treatment. There were no new safety issues in the study. IBD Newsletters Get exclusive IBD analysis and action news daily. SIGN UP NOW! IBD Newsletters Get exclusive IBD analysis and action news daily. Please enter a valid email address Please select a news

Bristol-Myers Squibb’s investigational cancer drug combination failed to meet the main goal of extending the lives of patients with lung cancer in a late-stage trial, Reuters reported. According to the article, the study was testing immunotherapy drug Opdivo in combination with Yervoy versus a placebo in patients with extensive-stage small cell lung cancer whose disease had not progressed after chemotherapy. Earlier this year, the FDA extended the date by which it was expected to make an approval decision on the combination to treat a different form a lung cancer, the article reported.   The Trump administration announced a new proposal aimed at lowering prescription drug costs for seniors by giving Medicare plans leverage in price negotiations, The Hill reported. According to the article, the plan would allow insurers that participate in Medicare’s prescription drug program to exclude protected drugs if prices rise faster than inflation, as well as certain new drug formulations t

Tom Petty’s song “I Won’t Back Down” has become a fight song for Ginny Hicks and Rick Rose. Both are in a battle with Stage 4 lung cancer. To keep one another’s spirits high, the two sign off every text, email or phone conversation with the words: “We won’t back down.” In just a year, Rose’s cancer has metastasized into bone cancer of the scapula. His adrenal gland is also compromised. While the circumstances are horrible, Rose says, “life goes on.” “I am not going to give up.” Hicks won’t let herself be dragged down by what she calls “the ebbs and flows” of her cancer. The edges of her tumor are growing, pushing on her airways, which leaves her short of breath and winded after doing routine yard work, such as raking leaves. She says her radiologist told her that the “white fluffy” specks seen on a recent scan means her lung “is not happy.” She’s also waiting the results of a biopsy of a spot on her liver. Both Hicks and Rose are grandparents of young boys. They remind each oth

A new American Lung Association report finds that Maine has one of the highest rates of new cases of lung cancer in the U.S. The report also finds that those Mainers who do get lung cancer are slightly likelier than the national average to survive it for five years. The report uses data from 2009-2013 and finds that Maine's incidence of lung cancer is just under 75 cases per 100,000 people, which is the sixth-worst rate in the country. https://ift.tt/2P5DPWS

Over the past 30 years, interventional cardiology has transformed heart care — replacing many interventions that used to require open-heart surgery with less invasive procedures. LISTEN UP: Add the new Michigan Medicine News Break to your Alexa-enabled device, or subscribe to our daily audio updates on iTunes , Google Play and Stitcher . Today, that same revolution has arrived for pulmonary medicine with interventional pulmonology, or IP. The subspecialty offers a variety of minimally invasive procedures to diagnose and treat both benign and cancerous disorders of the lungs and airways. The IP toolbox The foundation of IP is endoscopy, during which a doctor remotely manipulates tiny imaging or surgical tools through a thin tube placed in the body. “In IP, we use a range of endoscopic tools to look for and treat tumors, bleeding or inflammation in the lungs or airways, and to obtain fluid samples or tissue biopsies for testing,” explains Michigan Medicine interventional pulmonol

SCRANTON, LACKAWANNA COUNTY (WBRE/WYOU) - Breast cancer, colon cancer and pancreatic cancer are all among the deadliest forms of cancer. But each of those trails the number one cancer killer in the world: lung cancer.        The National Cancer Institute reports more than 150,000 Americans die annually of lung cancer. 3 million are currently under treatment for it. But as Eyewitness News Healthbeat Reporter Mark Hiller explains, how you're treated depends on how far along the cancer has progressed. "About three-quarters of people who are diagnosed with lung cancer come with a late stage lung cancer," said Geisinger Cardiothoracic Surgeon James Klena. So why do most lung cancer patients go without diagnosis until stage 3 or 4? Dr. Klena says it's because most are smokers who, because of their habit, already experience symptoms otherwise linked to lung cancer. "That is a cough, shortness of breath, frequent pneumonias." Unlike patients with stage 1 or 2 lu

Lung cancer is a certified killer, and it’s much more common than people realize. Of everyone who dies from cancer, more than a quarter will die from lung cancer. Lung cancer is the most common cancer in United States and worldwide. About 90 percent of lung cancer cases are from smoking, and the five-year survival rate is pretty dismal. A little more than half survive past five years if their cancer hasn’t spread yet when found, but that drops to less than one in five if it has spread. Only about 15 percent of patients are diagnosed at an early stage. If we can find and treat it at the early stage, we can have a better cure rate. While screenings exist for breast, colon, and other cancers, until 4 years ago there was no recommended reoccurring screening for patients at risk for lung cancer. Lung cancer screening patients who receive a low dose CT scan are 20 percent less likely to die from lung cancer than with standard screening chest X-rays. Should I be screened? — You should ge

FAYETTEVILLE, Ga. - Jennifer Kenney of Fayetteville, Georgia, remembers hearing the news 2 and a half years ago that stopped her in her tracks. "I was in disbelief,” the 63-year old payroll manager says.  “I just could not believe it.  Her brother Phil Jackson, who was also 63 at the time, and had never smoked, was diagnosed with lung cancer. "He's the healthiest one in the family,” Kenney remembers. “He watches his diet and runs." Kenney says their mother had smoked, and had been diagnosed with lung cancer years before she died of an unrelated illness. Her brother Phil had surgery, and Kenney says, for 2 years had no evidence of cancer. “This summer, we found out it had come back,” Kenney says.  “It had spread. It was up in his shoulder and his lung in two places." They got the news in July. "And, then, about a week later, I clearly heard God tell me, 'Get yourself checked.'” Kenney says. She was already scheduled to see Dr. Christine Lo

November 27, 2018 at 12:00a.m. By Mercy Health The mission of Mercy Health has remained steadfast since the Sisters of the Humility of Mary began providing health care services more than 100 years ago. Mercy Health’s core values of compassion, excellence, human dignity, justice, sacredness of life and service are upheld at all of our care locations, blending pioneering technology and innovative equipment to provide the best care possible. Visit mercy.com for more information or to find a doctor, location or specialty. Brought to you by Mercy Health Sometimes the smallest spot can lead to the largest concerns for patients. And rightfully so. It’s a scary predicament to learn that a nodule was detected in your lung cancer screening. But the positive news is that the presence of a nodule doesn’t necessarily mean it’s cancer – in fact in 95 percent of the cases it’s NOT cancer. Secondly, if it turns out to be of concern enough to a physician to be prescribed a follow-up v

DE SOTO, Kan.--( BUSINESS WIRE )--Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialization of personalized immunodiagnostics for the screening, detection and care of cancer, today announced that it has entered into an agreement with MultiPlan to expand access to Oncimmune’s Early CDT—Lung test. Early CDT—Lung is a simple, affordable, and extensively studied blood test that helps clinicians to optimize risk assessment of malignancy in indeterminate pulmonary nodules (IPNs). MultiPlan, Inc. is one of the most comprehensive providers of healthcare cost management solutions that includes primary, complementary and out-of-network strategies for managing the financial risks associated with healthcare claims. The company contracts with 900,000 healthcare providers across the U.S. and has an estimated 57 million consumers accessing MultiPlan network products. “We are successfully establishing agreements with regional and national commercial healt

Bristol-Myers Squibb’s investigational cancer drug combination failed to meet the main goal of extending the lives of patients with lung cancer in a late-stage trial, Reuters reported. According to the article, the study was testing immunotherapy drug Opdivo in combination with Yervoy versus a placebo in patients with extensive-stage small cell lung cancer whose disease had not progressed after chemotherapy. Earlier this year, the FDA extended the date by which it was expected to make an approval decision on the combination to treat a different form a lung cancer, the article reported.   The Trump administration announced a new proposal aimed at lowering prescription drug costs for seniors by giving Medicare plans leverage in price negotiations, The Hill reported. According to the article, the plan would allow insurers that participate in Medicare’s prescription drug program to exclude protected drugs if prices rise faster than inflation, as well as certain new drug formulations t

PRINCETON, N.J.--( BUSINESS WIRE )-- Bristol-Myers Squibb Company (NYSE: BMY) today announced that the Phase 3 CheckMate -451 study did not meet its primary endpoint of overall survival (OS) with Opdivo (nivolumab) 1 mg/kg in combination with Yervoy (ipilimumab) 3 mg/kg versus placebo as a maintenance therapy for patients with extensive-stage small cell lung cancer (SCLC) without disease progression after completion of first-line platinum-based chemotherapy. No new safety signals were observed with Opdivo 1 mg/kg plus Yervoy 3 mg/kg in this study. The Company will work with study investigators on the future publication of these results. About CheckMate -451 CheckMate -451 is a global, double-blind, randomized Phase 3 study evaluating Opdivo in combination with Yervoy and Opdivo monotherapy versus placebo as a maintenance therapy in patients with extensive-stage small cell lung cancer without disease progression after completion of first-line platinum-based chemotherapy. The